Biotransformation on the flavonolignan constituents of Silybi Fructus by an intestinal bacterial strain Eubacterium limosum ZL-II |
| |
| Affiliation: | 1. National Engineering Laboratory for Cereal Fermentation Technology, Jiangnan University, 1800 Lihu Road, Wuxi, Jiangsu 214122, China;2. Key Laboratory of Industrial Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, 1800 Lihu Road, Wuxi, Jiangsu 214122, China;3. The Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi 214122, China;4. Jiangsu Provisional Research Center for Bioactive Product Processing Technology, Jiangnan University, 1800 Lihu Road, Wuxi, Jiangsu 214122, China;1. De Montfort University, Leicester School of Pharmacy, The Gateway, Leicester LE1 9BH, UK;2. Department of Pharmacy, University of Patras, Patras 26504, Greece;3. Laboratory of Toxicology, University of Crete, Medical School, Voutes, Heraklion 71409, Crete, Greece;4. Laboratory of Clinical Virology, University of Crete, Medical School, Voutes, Heraklion 71409, Crete, Greece;1. Departamento de Tecnología de Alimentos, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA). Carretera de La Coruña km 7.5, 28040 Madrid, Spain;2. Unidad de Servicio de Técnicas Analíticas, Instrumentales y Microbiológicas (USTA), Instituto de Ciencia y Tecnología de Alimentos y Nutrición (ICTAN-CSIC), José Antonio Novais, 10, 28040 Madrid, Spain;1. Research Center of Natural Cosmeceuticals Engineering, Xiamen Medical College, No. 1999, Guankou Middle Rd., Jimei Dist., Xiamen City 361023, China;2. Department of Biological Science and Technology, China University of Science and Technology, No. 245, Sec. 3, Academia Rd., Nangang Dist., Taipei City 11581, Taiwan;1. Sorbonne Université, INSERM, UMRS U1269, Nutriomics Research Unit, Paris, France;2. Nutrition Department, Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Centre de Recherche en Nutrition Humaine d''Ile de France, Paris, France;3. Department of Vascular Medicine, University of Amsterdam Medical Center, Amsterdam, The Netherlands;4. Department of Internal Medicine, University of Amsterdam Medical Center, Free University, Amsterdam, The Netherlands |
| |
| Abstract: | Eubacterium limosum ZL-II is an anaerobic bacterium with demethylated activity, which was isolated from human intestinal bacteria in our previous work. In this study, the flavonolignan constituents of Silybi Fructus were biotransformed by E. limosum1 ZL-II, producing four new transformation products — demethylisosilybin B (T1), demethylisosilybin A (T2), demethylsilybin B (T3) and demethylsilybin A (T4), among which T1 and T2 were new compounds. Their chemical structures were identified by ESI-TOF/MS, 1H NMR, 13C NMR, HMBC and CD spectroscopic data. The bioassay results showed that the transformation products T1–T4 exhibited significant inhibitory activities on Alzheimer's amyloid-β 42 (Aβ422) aggregation with IC50 values at 7.49 μM–10.46 μM, which were comparable with that of the positive control (epigallocatechin gallate, EGCG3, at 9.01 μM) and much lower than those of their parent compounds (at not less than 145.10 μM). The method of biotransformation by E. limosum ZL-II explored a way to develop the new and active lead compounds in Alzheimer's disease from Silybi Fructus. However, the transformation products T1–T4 exhibited decreased inhibitory activities against human tumor cell lines comparing with their parent compounds. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
